SCHEMBL24426177

SCHEMBL24426177

CC(=O)c1ccc(NC(=O)N2CCN(c3cc(C)nc(Nc4ccc(N5CCOCC5)cc4)n3)CC2)cc1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 7/20 0.76
▸ FLT3 P36888 7/20 0.76
▸ MAPT P10636 8/20 0.59
▸ TP53 P04637 2/20 0.57
▸ MAPK1 P28482 2/20 0.57
▸ ALDH1A1 P00352 3/20 0.55
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ KDM4E B2RXH2 3/20 0.55
▸ POLB P06746 2/20 0.55
▸ PTGS2 P35354 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ THRB P10828 1/20 0.53
▸ PANK3 Q9H999 1/20 0.53
▸ ATM Q13315 1/20 0.53
▸ HTT P42858 1/20 0.50
▸ IGF1R P08069 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22860800 0.88 JAK2 (0.59) JAK2FLT3MAPTTP53MAPK1
SCHEMBL28445184 0.87 JAK2 (0.58) JAK2FLT3MAPTALDH1A1SMN1; SMN2
SCHEMBL24426212 0.86 JAK2 (1.00) JAK2FLT3MAPTTP53MAPK1
SCHEMBL28434553 0.84 MAPT (0.65) JAK2FLT3MAPTTP53MAPK1
SCHEMBL22860801 0.81 JAK2 (0.82) JAK2FLT3MAPTTP53MAPK1
SCHEMBL28445183 0.81 TAAR1 (0.54) JAK2FLT3
SCHEMBL29235929 0.81 JAK2 (0.84) JAK2FLT3MAPTTP53MAPK1
SCHEMBL24426218 0.80 PIK3R1 (0.70) JAK2FLT3MAPTMAPK1ALDH1A1
SCHEMBL24426171 0.79 JAK2 (0.81) JAK2FLT3MAPTTP53MAPK1
SCHEMBL24426217 0.79 JAK2 (0.83) JAK2FLT3MAPTTP53MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220259196-A1 2-AMINOPYRIMIDINE COMPOUND AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2022-08-18 — — US claimed
EP-3998254-A1 2-AMINOPYRIMIDINE COMPOUND AND APPLICATION THEREOF Shenyang Pharmaceutical University (CN) 2022-05-18 — — EP claimed
CN-113891881-A 2-aminopyrimidine compounds and application thereof 沈阳药科大学 2022-01-04 — — CN claimed
US-20220259196-A1 2-AMINOPYRIMIDINE COMPOUND AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2022-08-18 — — US disclosed
EP-3998254-A1 2-AMINOPYRIMIDINE COMPOUND AND APPLICATION THEREOF Shenyang Pharmaceutical University (CN) 2022-05-18 — — EP disclosed
EP-3998254-A1 2-AMINOPYRIMIDINE COMPOUND AND APPLICATION THEREOF Shenyang Pharmaceutical University (CN) 2022-05-18 — — EP disclosed
CN-113891881-A 2-aminopyrimidine compounds and application thereof 沈阳药科大学 2022-01-04 — — CN disclosed
CN-111423384-B 2-aminopyrimidine compounds and application thereof 沈阳药科大学 2021-10-15 — — CN disclosed
CN-111423384-A 2-aminopyrimidine compounds and application thereof 沈阳药科大学 2020-07-17 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259196-A1 2-AMINOPYRIMIDINE COMPOUND AND USES THEREOF DPYD, TPMT, TYMP JAK2 23/4885FLT3 35/4885MAPT 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback